title: Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats.
abstract: BACKGROUND
  Osborne-Mendel (OM) rats are prone to obesity when fed a high-fat diet, whereas S5B/Pl (S5B) rats are resistant to diet-induced obesity when fed the same diet. OM rats have a decreased satiation response to fatty acids infused in the gastrointestinal tract, compared to S5B rats. One possible explanation is that OM rats are less sensitive to the satiating hormone, glucagon-like peptide 1 (GLP-1). GLP-1 is produced in the small intestine and is released in response to a meal. The current experiments examined the role of GLP-1 in OM and S5B rats.
  
  
  METHODS
  Experiment 1 examined preproglucagon mRNA expression in the ileum of OM and S5B rats fed a high-fat (55% kcal) or low-fat (10% kcal) diet. Experiment 2 investigated the effects of a 2 h high-fat meal after a 24 h fast in OM and S5B rats on circulating GLP-1 (active) levels. Experiment 3 examined the effects of exendin-4 (GLP-1 receptor agonist) administration on the intake of a high-fat or a low-fat diet in OM and S5B rats.
  
  
  RESULTS
  Preproglucagon mRNA levels were increased in the ileum of OM rats compared to S5B rats and were increased by high-fat diet in OM and S5B rats. OM and S5B rats exhibited a similar meal-initiated increase in circulating GLP-1 (active) levels. Exendin-4 dose dependently decreased food intake to a greater extent in S5B rats compared to OM rats. The intake of low-fat diet, compared to the intake of high-fat diet, was more sensitive to the effects of exendin-4 in these strains.
  
  
  CONCLUSIONS
  These results suggest that though OM and S5B rats have similar preproglucagon mRNA expression in the ileum and circulating GLP-1 levels, OM rats are less sensitive to the satiating effects of GLP-1. Therefore, dysregulation of the GLP-1 system may be a mechanism through which OM rats overeat and gain weight.
authors.affiliation: Dietary Obesity Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA. Stefany.Primeaux@pbrc.edu
authors.forename: S D
authors.initials: SD
authors.lastname: Primeaux
authors.forename: M J
authors.initials: MJ
authors.lastname: Barnes
authors.forename: H D
authors.initials: HD
authors.lastname: Braymer
authors.forename: G A
authors.initials: GA
authors.lastname: Bray
mesh_terms: D000818:Animals; D004041:Dietary Fats / Q000008:administration & dosage*; D002149:Energy Intake / Q000235:genetics / Q000502:physiology; D000077270:Exenatide; D005786:Gene Expression Regulation / Q000235:genetics; D052216:Glucagon-Like Peptide 1 / Q000235:genetics / Q000378:metabolism*; D008297:Male; D009765:Obesity / Q000235:genetics / Q000378:metabolism*; D010455:Peptides / Q000235:genetics / Q000378:metabolism*; D052336:Proglucagon / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D012527:Satiation / Q000502:physiology*; D014688:Venoms / Q000235:genetics / Q000378:metabolism*; D015430:Weight Gain / Q000502:physiology
chemical_list: D004041:Dietary Fats; D010455:Peptides; D012333:RNA, Messenger; D014688:Venoms; D052336:Proglucagon; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide
references.citation: Peptides. 2008 Nov;29(11):1994-2000
references.pmid: 18765262
references.citation: Proc Natl Acad Sci U S A. 1983 Sep;80(18):5485-9
references.pmid: 6577439
references.citation: Trends Endocrinol Metab. 1999 Aug;10(6):229-235
references.pmid: 10407397
references.citation: Chem Senses. 2008 Jun;33(5):449-60
references.pmid: 18372387
references.citation: Nature. 1996 Jan 4;379(6560):69-72
references.pmid: 8538742
references.citation: Gastroenterology. 2007 May;132(6):2116-30
references.pmid: 17498507
references.citation: Gastroenterology. 2005 Jan;128(1):175-91
references.pmid: 15633135
references.citation: Endocrinology. 2001 Feb;142(2):521-7
references.pmid: 11159819
references.citation: Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 5:S42-7
references.pmid: 11840214
references.citation: Int J Obes (Lond). 2008 May;32(5):853-62
references.pmid: 18197182
references.citation: Endocrinology. 2009 Jun;150(6):2526-30
references.pmid: 19372201
references.citation: Physiol Behav. 2006 Nov 30;89(4):460-4
references.pmid: 16828127
references.citation: Peptides. 1997;18(5):657-61
references.pmid: 9213358
references.citation: Philos Trans R Soc Lond B Biol Sci. 2006 Jul 29;361(1471):1187-209
references.pmid: 16815798
references.citation: J Endocrinol. 2005 Feb;184(2):291-318
references.pmid: 15684339
references.citation: Peptides. 2006 Dec;27(12):3292-8
references.pmid: 16996647
references.citation: Drug News Perspect. 1998 Mar;11(2):92-7
references.pmid: 15616656
references.citation: Behav Brain Res. 2007 Jun 18;180(2):190-6
references.pmid: 17420059
references.citation: Physiol Behav. 1999 Jun;66(4):621-6
references.pmid: 10386906
references.citation: J Neuroendocrinol. 2006 Dec;18(12):883-94
references.pmid: 17076764
references.citation: Int J Obes (Lond). 2009 Apr;33 Suppl 1:S7-10
references.pmid: 19363513
references.citation: Auton Neurosci. 2004 Jan 30;110(1):36-43
references.pmid: 14766323
references.citation: Endocrinology. 1996 Nov;137(11):5159-62
references.pmid: 8895391
references.citation: Peptides. 2006 Jul;27(7):1644-51
references.pmid: 16426702
references.citation: Endocrinology. 2004 Jun;145(6):2660-5
references.pmid: 15044353
references.citation: Gastroenterology. 1994 Dec;107(6):1848-55
references.pmid: 7958701
references.citation: Obes Res. 2004 Jul;12(7):1067-76
references.pmid: 15292470
references.citation: Obes Res. 1998 Mar;6(2):147-56
references.pmid: 9545022
references.citation: Peptides. 2004 Dec;25(12):2171-7
references.pmid: 15572207
references.citation: Obesity (Silver Spring). 2006 Aug;14 Suppl 5:250S-253S
references.pmid: 17021376
references.citation: Obesity (Silver Spring). 2007 Mar;15(3):624-31
references.pmid: 17372312
references.citation: Diabetes. 2006 Dec;55(12):3387-93
references.pmid: 17130484